Merck updates CV pipeline

Merck & Co. Inc. (NYSE:MRK) provided an update on its cardiovascular programs Monday, including a reanalysis of data from the Phase III DEFINE trial of anacetrapib using a

Read the full 281 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE